EPCAM and neoplasm: Since the main difference in our previous CTC study, which identified CTCs as an independent prognostic marker for EC patients, lies in the current technique enriching for CK7/8 in addition to EpCAM, our results lead to the hypothesis that the CK7/8+/EpCAM+ or CK7/8+/EpCAM− CTC subtype does not lead to an advanced tumor staging tool in non-metastatic EC patients.